research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial
Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.
research MP-09.08
The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/research/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.
research Mesotherapy with bicalutamide: A new treatment for androgenetic alopecia
Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
research Selective Sensing of Darolutamide and Thalidomide in Pharmaceutical Preparations and in Spiked Biofluids
A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
research Characteristics of flutamide action on prostatic and testicular functions in the rat
Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
research [[Translated article]]RF- Mesotherapy with Bicalutamide: A Novel Alternative for Androgenetic Alopecia
RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
research Cyproteronacetat zur topischen Therapie androgenabhängiger Erkrankungen
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
research Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients
Oral bicalutamide is safe and effective for female hair loss.
research Testosterone replacement in the setting of Finasteride therapy: a therapeutic dilemma
research Response to “Improvement of female pattern hair loss with bicalutamide: a time-dependent process”
Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
research Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2
Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
research P6590Androgenic effects on ventricular repolarization: a translational study from pharmacovigilance databases to iPSC-cardiomyocytes
Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
research A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata
imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
research Faculty Opinions recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Optimization, characterization, and follicular targeting assessment of tretinoin and bicalutamide loaded niosomes
The niosomes effectively target hair follicles for acne treatment.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research 880 Triptolide (TRP), a diterpenoid, shows a strong efficacy and a safe profile in the topical treatment of actinic keratosis lesions in a UV-B-induced mouse model
Triptolide effectively and safely reduces actinic keratosis lesions in mice.
research Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse
Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
research Efficacy and Safety of Topical Flutamide 1% Gel as an Adjunctive Therapy in the Treatment of Patients With Acne Vulgaris
Topical Flutamide 1% gel effectively and safely reduces acne.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.